Recent Updates
Recently added Catalysts
LUCD Positive Sentiment Score: 70/100

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

Key Takeaway: Lucid Diagnostics Inc. has announced a scheduled business update conference call and webcast set for August 13, 2025. The call will be led by Lishan Aklog, M.D., the company's Chairman and CEO, and will include an overview of the company's operations and growth strategy. Additionally, CFO Dennis McGrath will present the financial results for the second quarter of 2025, providing insights into the company's performance.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lucid Diagnostics is holding a business update, showcasing their growth strategy.
  • The company provides innovative tools for early cancer detection, highlighting its commitment to preventing cancer.
  • The conference call is an opportunity for stakeholders to learn about financial results and company operations.

Full Press Release Details

Conference Call and Webcast at 8:30 AM Eastern Time
NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 financial results.
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
SOURCE Lucid Diagnostics

21 %

more press release views with

Frequently Asked Questions

When will Lucid Diagnostics host its business update conference call?

Lucid Diagnostics will host the call on Wednesday, August 13, 2025, at 8:30 AM ET.

Who will lead the business update call at Lucid Diagnostics?

Lishan Aklog, M.D., the Chairman and CEO of Lucid, will lead the call.

How can I access the Lucid Diagnostics conference call?

Listeners can dial 1-800-836-8184 in the U.S. or 1-646-357-8785 internationally.

Where can I find the replay of the conference call?

The replay will be available for 30 days on the investor relations section of luciddx.com.

What is the focus of Lucid Diagnostics?

Lucid Diagnostics focuses on cancer prevention for patients at risk of esophageal cancer.

Last updated: Jul 30, 2025